Zhao Z, Bourne P
J Chem Inf Model. 2024; 64(24):9517-9527.
PMID: 39656065
PMC: 11684028.
DOI: 10.1021/acs.jcim.4c00890.
Jiang M, Huizenga M, Mohr F, Amedi A, Bakker R, van den Berg R
J Med Chem. 2024; 67(14):12331-12348.
PMID: 38988250
PMC: 11284796.
DOI: 10.1021/acs.jmedchem.4c01037.
Klett T, Schwer M, Ernst L, Engelhardt M, Jaag S, Masberg B
Drug Des Devel Ther. 2024; 18:2653-2679.
PMID: 38974119
PMC: 11226190.
DOI: 10.2147/DDDT.S466829.
Alemi H, Khavandgar N, Oskouie I, Mardani-Fard H, Rostami T, AleTaha A
Medicine (Baltimore). 2024; 103(26):e38511.
PMID: 38941389
PMC: 11466090.
DOI: 10.1097/MD.0000000000038511.
Cao L, Wang L
Chem Rev. 2024; 124(13):8516-8549.
PMID: 38913432
PMC: 11240265.
DOI: 10.1021/acs.chemrev.4c00066.
Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib.
Barragan A, Ghaby K, Pond M, Roux B
J Chem Inf Model. 2024; 64(8):3488-3502.
PMID: 38546820
PMC: 11386585.
DOI: 10.1021/acs.jcim.4c00023.
A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.
Jiang M, Huizenga M, Wirt J, Paloczi J, Amedi A, van den Berg R
Nat Commun. 2023; 14(1):8039.
PMID: 38052772
PMC: 10698032.
DOI: 10.1038/s41467-023-43606-3.
Covalent targeting of non-cysteine residues in PI4KIIIβ.
Cosgrove B, Grant E, Bertrand S, Down K, Somers D, Evans J
RSC Chem Biol. 2023; 4(12):1111-1122.
PMID: 38033723
PMC: 10685791.
DOI: 10.1039/d3cb00142c.
Technologies for Direct Detection of Covalent Protein-Drug Adducts.
Mons E, Kim R, Mulder M
Pharmaceuticals (Basel). 2023; 16(4).
PMID: 37111304
PMC: 10146396.
DOI: 10.3390/ph16040547.
Molecular docking, molecular dynamics simulations and screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors.
Nassar H, Sippl W, Dahab R, Taha M
RSC Adv. 2023; 13(17):11278-11290.
PMID: 37057264
PMC: 10087387.
DOI: 10.1039/d3ra01145c.
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery.
McAulay K, Bilsland A, Bon M
Pharmaceuticals (Basel). 2022; 15(11).
PMID: 36355538
PMC: 9694498.
DOI: 10.3390/ph15111366.
Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands.
Sun J, Zhong H, Wang K, Li N, Chen L
Acta Pharm Sin B. 2021; 11(11):3417-3432.
PMID: 34900527
PMC: 8642439.
DOI: 10.1016/j.apsb.2021.02.023.
Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?.
Qin A, Musket A, Musich P, Schweitzer J, Xie Q
Neurooncol Adv. 2021; 3(1):vdab133.
PMID: 34806012
PMC: 8598918.
DOI: 10.1093/noajnl/vdab133.
Computational Study Reveals the Role of Water Molecules in the Inhibition Mechanism of LAT1 by 1,2,3-Dithiazoles.
Prejano M, Romeo I, La Serra M, Russo N, Marino T
J Chem Inf Model. 2021; 61(12):5883-5892.
PMID: 34788052
PMC: 8715508.
DOI: 10.1021/acs.jcim.1c01012.
Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies.
Edlund H, Buil-Bruna N, Vishwanathan K, Wei H, Raman R, de Kock M
Br J Clin Pharmacol. 2021; 88(5):2284-2296.
PMID: 34532877
PMC: 9298019.
DOI: 10.1111/bcp.15087.
Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors.
Seixas J, Sousa B, Marques M, Guerreiro A, Traquete R, Rodrigues T
RSC Chem Biol. 2021; 1(4):251-262.
PMID: 34458764
PMC: 8341910.
DOI: 10.1039/d0cb00033g.
Recent advances in the development of covalent inhibitors.
Kim H, Hwang Y, Kim M, Park S
RSC Med Chem. 2021; 12(7):1037-1045.
PMID: 34355176
PMC: 8292994.
DOI: 10.1039/d1md00068c.
Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.
Pang X, Liu X, Liu Y, Liu W, Li Y, Yu G
Molecules. 2021; 26(14).
PMID: 34299525
PMC: 8308130.
DOI: 10.3390/molecules26144250.
Discovery of a Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase with Oral Anti-Inflammatory Activity.
Tichenor M, Wiener J, Rao N, Pooley Deckhut C, Barbay J, Kreutter K
ACS Med Chem Lett. 2021; 12(5):782-790.
PMID: 34055226
PMC: 8155241.
DOI: 10.1021/acsmedchemlett.1c00044.
transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma.
Jia Z, Xing J, Li J, Wang W, Wang Y, Song Y
Transl Lung Cancer Res. 2021; 10(3):1383-1396.
PMID: 33889517
PMC: 8044484.
DOI: 10.21037/tlcr-21-107.
